ADDition of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial)

ADDition of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial)

Objectives: We evaluated the efficacy and safety of dapagliflozin, a SGLT2i along with ARNI in refractory HFrEF irrespective of their diabetic status. Methods: We performed a retrospective analysis of 104 symptomatic patients of HFrEF despite of optimal medical management with ARNI between January–J...

Full description

Bibliographic Details
Main Authors: Pankaj Jariwala, MD, DNB, DNB, MNAMS, FACC, FSCAI, Kartik Jadhav, MD, DM, Arshad Punjani, MD, Harikishan Boorugu, MD, Ajay Reddy Mari, MD
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:Indian Heart Journal
Subjects:
Dapagliflozin
SGLT2 inhibitors
Heart failure with reduced ejection fraction
ARNI
Refractory heart failure
Online Access:http://www.sciencedirect.com/science/article/pii/S0019483221001498

Internet

http://www.sciencedirect.com/science/article/pii/S0019483221001498

Similar Items